Charles Schwab’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-11,401
| Closed | -$130K | – | 3569 |
|
|
2023
Q4 | $130K | Buy |
+11,401
| New | +$89.6K | ﹤0.01% | 3328 |
|
|
2022
Q3 | – | Sell |
-1,023
| Closed | -$20K | – | 3563 |
|
|
2022
Q2 | $20K | Sell |
1,023
-4,337
| -81% | -$112K | ﹤0.01% | 3520 |
|
|
2022
Q1 | $267K | Buy |
5,360
+372
| +7% | +$19.3K | ﹤0.01% | 3248 |
|
|
2021
Q4 | $377K | Hold |
4,988
| – | – | ﹤0.01% | 3236 |
|
|
2021
Q3 | $395K | Sell |
4,988
-12,322
| -71% | -$1.24M | ﹤0.01% | 3207 |
|
|
2021
Q2 | $2.4M | Buy |
17,310
+1,672
| +11% | +$319K | ﹤0.01% | 2656 |
|
|
2021
Q1 | $3.27M | Buy |
15,638
+4,042
| +35% | +$810K | ﹤0.01% | 2497 |
|
|
2020
Q4 | $1.93M | Buy |
11,596
+694
| +6% | +$107K | ﹤0.01% | 2597 |
|
|
2020
Q3 | $1.85M | Buy |
10,902
+3,776
| +53% | +$545K | ﹤0.01% | 2513 |
|
|
2020
Q2 | $1.18M | Buy |
7,126
+2,552
| +56% | +$398K | ﹤0.01% | 2577 |
|
|
2020
Q1 | $530K | Buy |
4,574
+58
| +1% | +$8.15K | ﹤0.01% | 2692 |
|
|
2019
Q4 | $668K | Buy |
4,516
+44
| +1% | +$6.67K | ﹤0.01% | 2721 |
|
|
2019
Q3 | $611K | Buy |
4,472
+732
| +20% | +$103K | ﹤0.01% | 2725 |
|
|
2019
Q2 | $487K | Buy |
3,740
+723
| +24% | +$84K | ﹤0.01% | 2824 |
|
|
2019
Q1 | $286K | Buy |
+3,017
| New | +$396K | ﹤0.01% | 2951 |
|
Charles Schwab's HARP Position: Q1 2024 in Review
Charles Schwab sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 11,401 shares — an estimated $130K sold.
Charles Schwab first reported a position in HARP in Q1 2019 and held it in 15 quarters. The position peaked at $3.27M in Q1 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Charles Schwab reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Charles Schwab sold 11,401 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $130K.
- Charles Schwab first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
- Charles Schwab's Harpoon Therapeutics, Inc. Common Stock position peaked at $3.27M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.